SG Americas Securities
FENC icon

SG Americas Securities’s Fennec Pharmaceuticals FENC Stock Holding History

SG Americas Securities’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-11,678
Closed -$98K – 2936
2020
Q2 		$98K Buy
+11,678
New +$86.8K ﹤0.01% 3388

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

SG Americas Securities's FENC Position: Q3 2020 in Review

SG Americas Securities sold out of Fennec Pharmaceuticals (FENC) in Q3 2020, closing a stake of 11,678 shares — an estimated $98K sold.

SG Americas Securities first reported a position in FENC in Q2 2020 and held it in 1 quarter. The position peaked at $98K in Q2 2020. 55 funds tracked by Wall St. Rank hold FENC as of Q3 2020.

  • SG Americas Securities reported no remaining Fennec Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • SG Americas Securities sold 11,678 Fennec Pharmaceuticals shares in Q3 2020, an estimated $98K.
  • SG Americas Securities first reported a position in Fennec Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • SG Americas Securities's Fennec Pharmaceuticals position peaked at $98K in Q2 2020.
  • 55 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q3 2020.

Based on SG Americas Securities's 13F filing for Q3 2020, filed 9 Nov 2020.